Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators have revolutionized the therapeutic landscape in CF treatment. These vital drugs are extensively metabolized via CYP3A, so caution must be exercised in multimodal CF therapy because of the risk of adverse drug interactions. Our goal was to develop a highly sensitive assay for the purpose of therapeutic drug monitoring (TDM) in diagnostic laboratories.
After protein precipitation, the CFTR modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their metabolites ivacaftor-M1, ivacaftor-M6, and tezacaftor-M1 were separated with a two-dimensional chromatography setup within 5 min, and quantified with stable isotope-labeled internal standards. The method was validated according to the European Medicines Agency (EMA) guideline on bioanalytical method validation and applied to CF patient samples.
Inaccuracy was ≤7.0% and the imprecision coefficient of variation (CV) was ≤8.3% for all quality controls (QCs). The method consistently compensated for matrix effects, recovery, and process efficiency were 105–115 and 96.5–103%, respectively. Analysis of CF serum samples provided concentrations comparable to the pharmacokinetic profile data reported in the EMA assessment report for the triple combination therapy Kaftrio.
We hereby present a robust and highly selective isotope dilution liquid chromatography tandem mass spectrometry (ID-LC-MS/MS) assay for the simultaneous quantification of the so far approved CFTR modulators and their metabolites in human serum. The assay is suitable for state-of-the-art pharmacovigilance of CFTR modulator therapy in CF patients, in order to maximize safety and efficacy, and also to establish dose-response relationships in clinical trials.
Funding source: Friedrich-Baur-Stiftung
Research funding: Michael Paal received a research grant (award number 62/20) from the Friedrich-Baur-Stiftung. The funding source had no involvement in the research.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: Research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by the institutional review board of the Ludwig-Maximilians-Universität (protocol code 20-999).
3. Lopes-Pacheco, M. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol 2019;10:1662. https://doi.org/10.3389/fphar.2019.01662.Search in Google Scholar
4. Ramsey, BW, Davies, J, McElvaney, NG, Tullis, E, Bell, SC, Drevinek, P, et al.. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663–72. https://doi.org/10.1056/nejmoa1105185.Search in Google Scholar
5. Wainwright, CE, Elborn, JS, Ramsey, BW, Marigowda, G, Huang, X, Cipolli, M, et al.. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015;373:220–31. https://doi.org/10.1056/nejmoa1409547.Search in Google Scholar
6. Elborn, JS, Ramsey, BW, Boyle, MP, Konstan, MW, Huang, X, Marigowda, G, et al.. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respir Med 2016;4:617–26. https://doi.org/10.1016/s2213-2600(16)30121-7.Search in Google Scholar
7. Schneider, EK. Cytochrome P450 3A4 induction: lumacaftor versus ivacaftor potentially resulting in significantly reduced plasma concentration of ivacaftor. Drug Metabol Lett 2018;12:71–4. https://doi.org/10.2174/1872312812666180328105259.Search in Google Scholar
8. Taylor-Cousar, JL, Munck, A, McKone, EF, van der Ent, CK, Moeller, A, Simard, C, et al.. Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med 2017;377:2013–23. https://doi.org/10.1056/nejmoa1709846.Search in Google Scholar
9. Heijerman, HGM, McKone, EF, Downey, DG, Van Braeckel, E, Rowe, SM, Tullis, E, et al.. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019;394:1940–8. https://doi.org/10.1016/s0140-6736(19)32597-8.Search in Google Scholar
10. Middleton, PG, Mall, MA, Drevinek, P, Lands, LC, McKone, EF, Polineni, D, et al.. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019;381:1809–19. https://doi.org/10.1056/nejmoa1908639.Search in Google Scholar PubMed PubMed Central
11. Mehta, G, Macek, MJr, Mehta, A, European Registry Working G. Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries. J Cyst Fibros 2010;9(2 Suppl):S5–21. https://doi.org/10.1016/j.jcf.2010.08.002.Search in Google Scholar
12. Committee for Medicinal Products for Human Use (CHMP). Assessment report Kalydeco (ivacaftor). Amsterdam: European Medicines Agency (EMA). EMA/473279/2012. Procedure No.: EMEA/H/C/002494/0000; 2012.Search in Google Scholar
13. Committee for Medicinal Products for Human Use (CHMP). Assessment report Symkevi (tezacaftor/ivacaftor). Amsterdam: European Medicines Agency (EMA). EMA/567306/2018. Procedure No.: EMEA/H/C/004682/0000; 2018.Search in Google Scholar
14. Committee for Medicinal Products for Human Use (CHMP). Assessment report Kaftrio (ivacaftor/tezacaftor/elexacaftor). Amsterdam: European Medicines Agency (EMA). EMA/385871/2020. Procedure No.: EMEA/H/C/005269/0000; 2020.Search in Google Scholar
15. Committee for Medicinal Products for Human Use (CHMP). Assessment report Orkambi (lumacaftor/ivacaftor). Amsterdam: European Medicines Agency (EMA). EMA/843650/2018. Procedure No.: EMEA/H/C/003954/X/0034/G; 2018.Search in Google Scholar
17. Schneider, EK, Reyes-Ortega, F, Wilson, JW, Kotsimbos, T, Keating, D, Li, J, et al.. Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO. J Chromatogr B Anal Technol Biomed Life Sci 2016;1038:57–62. https://doi.org/10.1016/j.jchromb.2016.10.026.Search in Google Scholar
18. Schneider, EK, Reyes-Ortega, F, Li, J, Velkov, T. Optimized LC-MS/MS method for the high-throughput analysis of clinical samples of ivacaftor, its major metabolites, and lumacaftor in biological fluids of cystic fibrosis patients. JoVE 2017;128:56084. https://doi.org/10.3791/56084.Search in Google Scholar
19. Reyes-Ortega, F, Qiu, F, Schneider-Futschik, EK. Multiple reaction monitoring mass spectrometry for the drug monitoring of ivacaftor, tezacaftor, and elexacaftor treatment response in cystic fibrosis: a high-throughput method. ACS Pharmacol Transl Sci 2020;3:987–96. https://doi.org/10.1021/acsptsci.0c00103.Search in Google Scholar
21. European Medicines Agency. Guideline on bioanalytical method validation. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf [Accessed 21 Jan 2021].Search in Google Scholar
22. Bonfiglio, R, King, RC, Olah, TV, Merkle, K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun Mass Spectrom 1999;13:1175–85. https://doi.org/10.1002/(sici)1097-0231(19990630)13:12<1175::aid-rcm639>3.0.co;2-0.10.1002/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.0.CO;2-0Search in Google Scholar
23. Matuszewski, BK, Constanzer, ML, Chavez-Eng, CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003;75:3019–30. https://doi.org/10.1021/ac020361s.Search in Google Scholar
24. Dekkers, R, Vijftigschild, LA, Vonk, AM, Kruisselbrink, E, de Winter-de Groot, KM, Janssens, HM, et al.. A bioassay using intestinal organoids to measure CFTR modulators in human plasma. J Cyst Fibros 2015;14:178–81. https://doi.org/10.1016/j.jcf.2014.10.007.Search in Google Scholar
25. Singh, N, Bansal, P, Maithani, M, Chauhan, Y. Development and validation of a novel stability-indicating RP-HPLC method for simultaneous determination of tezacaftor and ivacaftor in fixed dose combination. J Chromatogr Sci 2020;58:346–54. https://doi.org/10.1093/chromsci/bmz120.Search in Google Scholar
26. Iguiniz, M, Heinisch, S. Two-dimensional liquid chromatography in pharmaceutical analysis. Instrumental aspects, trends and applications. J Pharmaceut Biomed Anal 2017;145:482–503. https://doi.org/10.1016/j.jpba.2017.07.009.Search in Google Scholar PubMed
27. Baumann, P, Hiemke, C, Ulrich, S, Eckermann, G, Gaertner, I, Gerlach, M, et al.. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004;37:243–65. https://doi.org/10.1055/s-2004-832687.Search in Google Scholar PubMed
28. Schoretsanitis, G, Paulzen, M, Unterecker, S, Schwarz, M, Conca, A, Zernig, G, et al.. TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World J Biol Psychiatr 2018;19:162–74. https://doi.org/10.1080/15622975.2018.1439595.Search in Google Scholar PubMed
The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2021-0724).
© 2021 Walter de Gruyter GmbH, Berlin/Boston